Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16217481 | 0.84 | PRMT5 (0.73) | PRMT5WDR77 | |
| SCHEMBL16217448 | 0.79 | PRMT5 (0.75) | PRMT5WDR77 | |
| SCHEMBL19633784 | 0.78 | PRMT5 (0.73) | PRMT5WDR77 | |
| SCHEMBL16217484 | 0.77 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL19633809 | 0.73 | PRMT5 (0.65) | PRMT5WDR77 | |
| SCHEMBL19633726 | 0.73 | PRMT5 (0.65) | PRMT5WDR77 | |
| SCHEMBL32617552 | 0.73 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL32617555 | 0.73 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL15825446 | 0.73 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL32617554 | 0.73 | PRMT5 (0.79) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391089-B2 | PRMT5 inhibitors and uses therof | Epizyme, Inc. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391089-B2 | PRMT5 inhibitors and uses therof | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 27/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.